{
  "image_filename": "table_p4_det_3_003.png",
  "image_path": "Treanor_et_al.__2011_/extracted/figures/table_p4_det_3_003.png",
  "image_type": "Table",
  "page_number": 4,
  "block_id": "det_3_003",
  "claim_id": "claim_006",
  "claim": "Flublok is produced using a novel production platform in which recombinant HA is expressed in insect cells using a baculovirus expression vector system (BEVS).",
  "supports_claim": false,
  "explanation": "A table showing pre-vaccination (day 0) and post-vaccination (day 28) geometric mean antibody titers (with 95% CI) and % response rates for three influenza vaccine antigens (A/Solomon Island/3/2006 H1N1, A/Wisconsin/67/2005 H3N2, B/Malaysia/2506/2004) across four groups: Placebo, FluBlok, FluBlok PV, and FluBlok NPV. does not support the claim because the table presents immunogenicity outcomes and response rates, without any information on the Flublok production platform or use of recombinant HA expression in insect cells via BEVS.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A table showing pre-vaccination (day 0) and post-vaccination (day 28) geometric mean antibody titers (with 95% CI) and % response rates for three influenza vaccine antigens (A/Solomon Island/3/2006 H1N1, A/Wisconsin/67/2005 H3N2, B/Malaysia/2506/2004) across four groups: Placebo, FluBlok, FluBlok PV, and FluBlok NPV.",
    "evidence_found": null,
    "reasoning": "does not support the claim because the table presents immunogenicity outcomes and response rates, without any information on the Flublok production platform or use of recombinant HA expression in insect cells via BEVS.",
    "confidence_notes": null
  }
}